Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
- 1 May 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 19 (5), 1134-1147
- https://doi.org/10.1158/1535-7163.mct-19-0461
Abstract
The development of efficacious therapies targeting metastatic spread of breast cancer to the brain represents an unmet clinical need. Accordingly, an improved understanding of the molecular underpinnings of central nervous system spread and progression of breast cancer brain metastases (BCBM) is required. In this study, the clinical burden of disease in BCBM was investigated, as well as the role of aldehyde dehydrogenase 1A3 (ALDH1A3) in the metastatic cascade leading to BCBM development. Initial analysis of clinical survival trends for breast cancer and BCBM determined improvement of breast cancer survival rates; however, this has failed to positively affect the prognostic milestones of triple-negative breast cancer (TNBC) brain metastases (BM). ALDH1A3 and a representative epithelial–mesenchymal transition (EMT) gene signature (mesenchymal markers, CD44 or Vimentin) were compared in tumors derived from BM, lung metastases (LM), or bone metastases (BoM) of patients as well as mice after injection of TNBC cells. Selective elevation of the EMT signature and ALDH1A3 were observed in BM, unlike LM and BoM, especially in the tumor edge. Furthermore, ALDH1A3 was determined to play a role in BCBM establishment via regulation of circulating tumor cell adhesion and migration phases in the BCBM cascade. Validation through genetic and pharmacologic inhibition of ALDH1A3 via lentiviral shRNA knockdown and a novel small-molecule inhibitor demonstrated selective inhibition of BCBM formation with prolonged survival of tumor-bearing mice. Given the survival benefits via targeting ALDH1A3, it may prove an effective therapeutic strategy for BCBM prevention and/or treatment.Keywords
Other Versions
Funding Information
- NIH (R01NS083767, R01NS087913, R01CA183991, R01CA201402)
This publication has 64 references indexed in Scilit:
- Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3Proceedings of the National Academy of Sciences of the United States of America, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathwayNeuro-Oncology, 2011
- Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine NetworksCancer Research, 2011
- Aldehyde Dehydrogenase Activity of Breast Cancer Stem Cells Is Primarily Due To Isoform ALDH1A3 and Its Expression Is Predictive of MetastasisThe International Journal of Cell Cloning, 2010
- Organ-specific enhancement of metastasis by spontaneous ploidy duplication and cell size enlargementCell Research, 2010
- Genes that mediate breast cancer metastasis to the brainNature, 2009
- Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular SignatureCancer Research, 2009
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- Beyond tumorigenesis: cancer stem cells in metastasisCell Research, 2006